HomeCompareDMTK vs EPRT

DMTK vs EPRT: Dividend Comparison 2026

DMTK yields 2127.66% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DMTK wins by $17707088693.31M in total portfolio value
10 years
DMTK
DMTK
● Live price
2127.66%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17707088693.38M
Annual income
$16,208,512,607,342,262.00
Full DMTK calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — DMTK vs EPRT

📍 DMTK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDMTKEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DMTK + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DMTK pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DMTK
Annual income on $10K today (after 15% tax)
$180,851.06/yr
After 10yr DRIP, annual income (after tax)
$13,777,235,716,240,922.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, DMTK beats the other by $13,777,235,716,230,008.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DMTK + EPRT for your $10,000?

DMTK: 50%EPRT: 50%
100% EPRT50/50100% DMTK
Portfolio after 10yr
$8853544346.72M
Annual income
$8,104,256,303,677,551.00/yr
Blended yield
91.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

DMTK
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$7.50
+7878.7% upside vs current
Range: $7.50 — $7.50
Altman Z
-8.4
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DMTK buys
0
EPRT buys
0
No recent congressional trades found for DMTK or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDMTKEPRT
Forward yield2127.66%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$17707088693.38M$63.4K
Annual income after 10y$16,208,512,607,342,262.00$12,840.73
Total dividends collected$17601219228.91M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$7.50$35.50

Year-by-year: DMTK vs EPRT ($10,000, DRIP)

YearDMTK PortfolioDMTK Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$223,466$212,765.96$11,205$505.18+$212.3KDMTK
2$4,682,655$4,443,546.58$12,672$682.46+$4.67MDMTK
3$92,031,981$87,021,539.62$14,490$930.48+$92.02MDMTK
4$1,696,889,334$1,598,415,114.79$16,786$1,282.69+$1696.87MDMTK
5$29,359,261,977$27,543,590,390.03$19,753$1,791.56+$29359.24MDMTK
6$476,792,027,971$445,377,617,654.91$23,677$2,541.64+$476792.00MDMTK
7$7,269,883,644,738$6,759,716,174,809.65$29,008$3,672.99+$7269883.62MDMTK
8$104,104,693,867,782$96,325,918,367,911.80$36,463$5,425.08+$104104693.83MDMTK
9$1,400,538,398,162,041$1,289,146,375,723,514.20$47,238$8,221.57+$1400538398.11MDMTK
10$17,707,088,693,375,648$16,208,512,607,342,262.00$63,385$12,840.73+$17707088693.31MDMTK

DMTK vs EPRT: Complete Analysis 2026

DMTKStock

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Full DMTK Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this DMTK vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DMTK vs SCHDDMTK vs JEPIDMTK vs ODMTK vs KODMTK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.